David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk. David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech. David Stermanon

Analyst Articles

Investors looking to score big gains should always pay attention to the retail sector. Not the top retail stocks that seem to pound out modest sales gains each year, but the weaker retailers that have hit a rough patch. These retail firms could see shares slide far below prior peaks once same-store sales weaken and investors shun them. Yet these broken retailers can also become vastly oversold — and great bargain-hunting fodder. For example, I suggested that women’s apparel retailer Christopher & Banks (NYSE: CBK) was far too cheap — based on… Read More

Investors looking to score big gains should always pay attention to the retail sector. Not the top retail stocks that seem to pound out modest sales gains each year, but the weaker retailers that have hit a rough patch. These retail firms could see shares slide far below prior peaks once same-store sales weaken and investors shun them. Yet these broken retailers can also become vastly oversold — and great bargain-hunting fodder. For example, I suggested that women’s apparel retailer Christopher & Banks (NYSE: CBK) was far too cheap — based on tangible book value and sure enough, the stock eventually took off like a rocket. In fact, a number of oversold retailers make up the list of leading gainers in the just completed third quarter. In almost every instance, these retailers had traded sharply lower in prior quarters, which is precisely the time that you should be focusing on them. Whether it’s a buyout offer, or simply a… Read More

Transitioning from a niche drug maker into a “Big Pharma player” can be fraught with challenges. As these companies seek to grow through the development or acquisition of new drugs, they need to keep an eye on their existing portfolios of products… Read More